| Drug General Information |
| Drug ID |
D0D9RL
|
| Former ID |
DNC013739
|
| Drug Name |
(-)-eseroline
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C13H18N2O
|
| Canonical SMILES |
CC12CCN(C1N(C3=C2C=C(C=C3)O)C)C
|
| InChI |
1S/C13H18N2O/c1-13-6-7-14(2)12(13)15(3)11-5-4-9(16)8-10(11)13/h4-5,8,12,16H,6-7H2,1-3H3/t12-,13+/m1/s1
|
| InChIKey |
HKGWQUVGHPDEBZ-OLZOCXBDSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Delta-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Mu-type opioid receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction
|
|
Estrogen signaling pathway
|
|
Morphine addiction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Enkephalin release
|
|
Opioid proenkephalin pathway
|
|
Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Pathway Interaction Database
|
IL4-mediated signaling events
|
|
Reactome
|
Peptide ligand-binding receptors
|
|
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
|
Peptide GPCRs
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP69:TCR Signaling Pathway
|
|
Opioid Signalling
|
|
GPCR downstream signaling
|
| References |
| REF 1 | Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4. |
|---|
